BioCentury
ARTICLE | Product Development

Back for seconds

Roche picks PTC's small molecule for spinal muscular atrophy

December 12, 2011 8:00 AM UTC

A second deal between Roche and PTC Therapeutics Inc. demonstrates both the pharma's increasing push into CNS diseases, and its confidence in PTC's small molecule approaches to modifying RNA biology.

Last month, the partners announced Roche licensed exclusive rights to a preclinical program for spinal muscular atrophy (SMA) in exchange for $30 million up front, up to $460 million in milestones and potential double-digit royalties...